Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Support Services
EPIC: FIP
Latest Price: 57.50  (0,00%)
52-week High: 78.50
52-week Low: 42.50
Market Cap: 62.93M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Fusion IP
www.fusionip.co.uk

Fusion IP owns the rights to 100% of university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to develop some of the world's most advanced and exciting science, in fields as varied as clean energy, electronics, engineering and medicine; turning world class research into valuable businesses through the creation of portfolio of companies.

Full Fusion IP profile here
Pdf

Fusion IP Diurnal's key drug moves to Phase II trials

22nd Jun 2012, 3:44 am by Philip Whiterow

Fusion IP (LON:FIP) portfolio company and drug developer Diurnal has completed the Phase I trial for its lead product Chronocort and raised £1.2 mln to take the drug through Phase II.

Fusion put up £440,000 of the new funds to maintain its stake in Diurnal at 43.1 per cent.

Diurnal said the £1.2 million funding will enable the company to complete its Phase II trials, due to commence in July 2012, with an estimated Phase II completion date of mid-2013.

Chronocort is a drug delivery system for people suffering from reduced levels of the key hormone cortisol (hydrocortisone).

Congenital adrenal hyperplasia and adrenal insufficiency are the diseases associated with cortisol deficiency and both require life-long treatment.

Victims of adrenal insufficiency, for example, cannot produce enough cortisol, an essential stress hormone, and must administer hydrocortisone in its place.

Chronocort delivers hydrocortisone in a manner that mimics the body's normal cycle.

The new drug has already received two Orphan Drug designations from the European Medicines Agency, which gives it a ten-year exclusive licence once it gets marketing authorisation in Europe.

Peter Grant, operations director for Fusion IP, said: "This is tremendous news for Diurnal. The Phase I results were excellent and the company is now moving immediately to start it's Phase II trials. With results due in mid-2013, we are very excited about Diurnal's prospects."

Martin Whitaker, general manager at Diurnal, added that if all goes to plan Chronocort could start to generate revenues from 2015.

Cardiff-based Diurnal is a spin-out from the University of Wales, which has granted Fusion IP exclusive access to all IP generated by its research department.

Fusion IP also has a Memorandum of Understanding with Finance Wales, which provides commercial funding to Wales-based SMEs, to co-invest in opportunities arising from the research agreement.

Melanie Goward, senior investment executive at Finance Wales, added: "This is a major turning point for Chronocort and we are pleased to continue to back Diurnal.”

 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here